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Abstract
This research project aims to create gold nanoparticles (AuNPs) functionalized with PLGA
(poly(lactic co-glycolic acid)) polymers for generating reactive oxygen species (ROS) by way of Xray irradiation for use in cancer therapies.1–3 The current methods of cancer treatment rely on
drugs and/or chemotherapy depending on the type of cancer present; these methods come
with varying success rates which are also dependent on how severe the condition has become
(the lower the severity, the higher chance of success). The latest method of cancer treatment is
proton beam radiation therapy (PBRT) which can be specific in its targeting but not very cost
effective; and its efficacy with all types of cancers has yet to be confirmed.4 Chemotherapies
and cancer drugs, while successful, are indiscriminate in distinguishing the healthy cells from
the malignant cells which in turn, causes immune deficiencies and toxicity concerns. 5 By using
appropriately functionalized AuNPs, they can be sent to the site of the tumor where they can
be irradiated with X-rays to generate ROS to destroy cancer cells; to increase the compatibility
of the functionalized AuNPs, they co-precipitated with water soluble poly(vinyl alcohol) (PVA).
By using a photosensitizer 1,3-diphenylisobenzofuran (DPBF) dissolved with the functionalized
AuNPs, we can determine the quantum yield of ROS generation via UV/Vis spectrometry.6,7 This
paper outlines the method used to synthesize a PDLLA (poly(DL-lactic acid)) polymer ligand with
a dithiol anchor which was then dissolved with synthesized citrate capped AuNPs to undergo
ligand exchange – the extent of ligand exchange will also be explored via various spectroscopic
techniques.8–11 These products will be characterized through NMR (nuclear magnetic
resonance), IR (infrared red), MALDI (matrix assisted laser desorption ionization) and SEC (size
exclusion chromatography) to determine molecular weight, functional groups and polymer
yield and purity. Other methods such as STEM (scanning transmission electron microscopy), DLS
(dynamic light scattering), to confirm size, shape of the AuNPs and stability of the polymer on
the surface of the AuNPs.
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1. Polymer capped nanoparticles as therapies for cancer treatment
A. Background
i.

Current Cancer Treatments

With cancer (lung, breast, colon, etc.) being the second leading cause of death in the US
according to the Center for Disease Control (CDC) there have been many efforts to find a
method that will be able to not only remove cancer cells but prevent them from returning. The
most conventional and cost-effective way of treating cancer therapies is through
immunotherapies, radiation therapies, surgery, and chemotherapies.12–14 These methods are
also often pieced together depending on the size of the tumor in question (i.e. patients will
undergo surgery first to make the tumor smaller before undergoing chemotherapy or radiation
therapy).14
One of the newest methods that has cropped up for use in cancer treatment is proton
beam radiation therapy (PBRT). This method utilizes a synchrotron to essentially spin protons
(outside source) at high speeds to excite them; by aiming the excited protons at the tumor site,
they create a beam which eject electrons from the tumor cells that will irradiate the tumor.4,15
While this idea of using protons to radiate tumors is not new, it hasn’t become more
popular/commercially available (for lack of a better phrase) until recently (within the last ten
years). Because PBRT treatments is still relatively new, access to this therapy can be difficult
with only a handful of facilities able to house the equipment necessary. This in turn makes
receiving this therapy rather expensive – it is on average, four to five times more expensive
than other types of cancer therapies.4 This method allows for more specific targeting of tumors
which is ultimately beneficial to the patient – the more specific the target, the less damage
there is to other healthy cells.16 However, this treatment hasn’t shown efficacy in treating all
types of cancers; there is only data for some and it is unclear whether or not it is efficient in
completely removing the cancer cells as well as any side effects that may could arise to the
patient.16 Within the same thought, without knowing any possible long term or short term side
effects, it is difficult to know what could done to address it.16
Another type of cancer treatment like the method that is the focus of this paper, is
photodynamic therapy (PDT). This type of therapy utilizes a light source to activate a

photosensitive drug or agent to kill cancer cells.17,18 This method also utilizes reactive oxygen
species (ROS) generation to treat cancer cells of various forms – using a light source to excite
the photosensitizer to generate superoxide and oxygen radicals. This method relies on the
photosensitive drugs to be able to penetrate the skin or travel to its intended site before being
exposed to the light source. This comes with several different problems: (1) administering the
drug intravenously does not guarantee that 100% of that drug will arrive at its intended site
which can cause side reactions in unintended areas when exposed to the light source, (2) and
the light source used may not penetrate the skin enough to trigger ROS generation in a
significant way, and (3) the reaction is dependent on the oxygen concentration within the
tumor cell but since tumor cells experience hypoxia, there are still efforts to make these drugs
oxygen-independent.17 While each problem is being addressed individually, it is unclear
whether the solutions to these three problems could be addressed within one drug. This paper
aims to speak to a method that would improve upon this method without the use of
pharmaceutical drugs and still generate ROS in a significant enough amount to damage tumor
cells.

ii.

Role of polymers for delivery of ROS-generating species

The use of polymers in conjunction with various types of nanoparticles has shown to help to
increase the efficacy of the nanoparticles.2 While polymers are most known to be used in
different plastic items – disposable utensils, coffee cup lids, soup lids, gloves etc. – their use in
other applications is not as well known. Using different types polymers in medicine has grown
in the last decade with multiple studies on the use of polymer functionalized nanoparticles of
various composition to increase efficacy of drugs already on the market and the loading of
various dyes or imaging agents.2 While there are multiple different types of polymers –
polycaprolactones, polyacrylates, polyamides etc. – that are used for different medical uses, the
polymer group that this paper will focus on are polyesters. In particular, poly(lactic acid) and it’s
copolymer poly(lactic-co-glycolic acid).
Poly(lactic-co-glycolic acid) (PLGA) is commonly co-precipitated – dissolved in the same
solvent then precipitated with nonsolvent and precipitate is filtered out – with drugs, imaging
2

agents and/or targeting moieties to afford polymer-based structures that are for a wide range
of therapies.19,20 The PLGA medium acts to solubilize and protect hydrophobic drugs, and to
control their release.2,21 Loading PLGA precipitates with metal, metal oxide or quantum dot
nanocrystals represents an opportunity for accessing new therapeutic strategies where
enhanced directing, imaging and drug action can be established.21 There are significant
challenges in this area however, such as poor loading efficiency (how much drug the particle
can be taken up), stability, mixing and dispersion of the NPs in the PLGA.19,20 Gold nanoparticles
(AuNPs)s – which will be introduced in a later sections – are particularly attractive candidate
for nanomaterials as they have recently been found to assist with the generation of reactive
oxygen species (ROS) for cancer therapy.
Poly(D,L-lactic acid), PDLLA, is the parent polymer of the PLGA copolymer, where the
glycolic acid content of the copolymer has been eliminated. PDLLA is a well-documented
biodegradable polymer that is compatible with many biological systems; it can be delivered into
biological systems with modest negative impacts to the host tissue or system, making it an
attractive polymer to use when using it for medical applications.2,21,22 One of the biggest
argument for the use of PLGA is that is US FDA approved for drug delivery due to its
biocompatibility.2,23 This is due to the fact that they undergo hydrolysis of the ester linkages to
produce their monomers which are byproducts of various metabolic pathways which show little
to no toxicity when doing in vivo and in vitro studies.22 By introducing a biocompatible material
into a biological system, the nanoparticles can be sent to the target area (tumor site) without
risk of them becoming destabilized (aggregation of particles, ligands being removed from
surface etc.), causing toxicity problems, or dissociating within the body rendering them
unusable. This also has the added advantage of prolonging any release or action of any cancer
drugs that may be loaded into the particle as well.
The uses for PLGA range between surgical sutures and scaffolding for surgical
reconstruction as well as cancer drug loaded PLGA particles.24 Cancer drugs such as cis-platin,
show lower toxicity rates when loaded within PLGA nanoparticles – allowing for a lower dosage
while still maintain the same efficacy.24 The benefits of using PLGA as the main polymer stem
from the fact that lactic acid is already produced within the body naturally and glycolic acid is
3

not harmful for the body (as stated above). These compounds can be broken down by the body
naturally with no harm done to the host. The main difference between PDLLA and PLGA stem
from the amount of time that it takes to dissolve within the body – by installing randomized
glycolic acid units within the parent polymer, the polymer will dissolve at a faster but more
controlled rate.2,21 In the example of sutures for surgical procedures, PDLLA based sutures may
not dissolve for several months while the PLGA based sutures will dissolve within a couple
weeks to days.
While PLGA and PDLLA are biocompatible, their solubility in water is not ideal. To
improve their solubility in water, a surfactant or dispersant is needed. Poly(vinyl alcohol) (PVA)
is the surfactant of choice for this procedure due to its biocompatibility and mechanical
properties which make it another candidate for surgical scaffolding and drug delivery. 25,26
Studies have shown PVA, like PLGA has improved drug delivery – longer lasting delivery – and
mucoadhesion (the ability for two materials to adhere to each other for a period of time) in the
case of using it as a scaffold for wound dressing.25 This allows it to remain stable and still
perform its intended purpose.

iii.

Benefits of gold nanoparticles

The use of nanoparticles in medicine has seen many strides the last hundred years due to their
ease of synthesis, use, and multiple benefits when being used for various medical applications.
With nanoparticles being one billionth (1 nm = 10-9 m) the size of an item 1 meter in size and
most being soluble in water, they are useful for any applications that involve small apertures
where normal needles, tubes or other larger items could not reach. They can be made from any
material as their core such as silver or gold through similar synthesis methods, stabilizing the
particles with a capping ligand/reducing agent (trisodium citrate, cetrimonium bromide (CTAB),
or tris(2-carboxyethyl)phosphine (CTAB)) which can then be further tuned (size and properties)
by exchanging ligands as well as synthesizing different sized nanoparticles.27,28 This can also be
applied to polymers as well through emulsions and be further tuned in an analogous manner as
the gold nanoparticles. The main methods for synthesizing particles are through the reduction
of gold with the reducing agent that were listed earlier (they will then become the capping
4

ligand on the surface), or through controlled seeding process (multiple additions of a premade
gold and reducing agent solutions to gain desired size).9,29
These nanoparticles – this paper will focus on gold nanoparticles (AuNPs) in particular –
have shown to aid in the efficacy of drug loading as well as acting as a radiosensitizer to allow
for more specific drug targeting to treat multiple diseases/illnesses. They are easy to synthesize
with tunable sizes and shapes, and they are easy to detect with different imaging
techniques.21,30 They are most notably used for different methods of targeted drug delivery or
cancer diagnoses and can be conjugated with various drugs to be sent to the intended target
site (i.e. tumor site) which allows for a targeted cancer treatment (shown in Figure 1). Due to
their stability, biocompatibility, low toxicity, and tunable size (the optimal size being around
20nm -100 nm), they are a fast-growing material to be used in various medical applications.30
Several different particles have been recently synthesized and studied to be used for
imaging and cancer therapies; these particles rely on thiolated amine group polymers as the
main stabilizing ligand.28,31 The currently commercially available polymer coated particles are
functionalized with poly(ethylene glycol) (PEG) which can be bought and used for experiments.
However, there two main problems that arise with the use of these particles: 1) there are issues
with cytotoxicity (toxicity to cells) with the gold particles as they aggregate as well as the
ligands themselves and 2) cost as the PEGylated AuNPs are rather costly to buy from a supplier
if one was unable to synthesize the particles themselves. To address the first issue, by using
gold that is functionalized with a biocompatible polymer such as PLGA, co-precipitated in PVA
(another biocompatible and water-soluble polymer), the possibility of cytotoxicity will drop.
The second stated concern is not currently within the scope of this paper.

5

Figure 1. The big picture of what will be expected of the functionalized gold nanoparticles;
using targeted nanotherapeutics to remove cancer cells and leave healthy cells.

While the overall interactions between the surface of the gold and thiols have not fully
been characterized beyond Van der Waals interactions, it is known that it is a favorable bond
and provides stability to the particle overall.21,30,32 As stated previously, the use of trisodium
citrate as a reducing agent/capping ligand has been widely used and can also be used to aid in
ligand exchange by keeping the gold stable as a dithiol ligand is grafted to the surface. 27 By
synthesizing a dithiol-functional group as the initiator for the ROP, we can have an energetically
6

stable bond between the dithiol terminated ligand and the surface of the gold. By installing a
bidentate (two anchor points) thiol ligand is expected to favor additional stability in the
polymer-capped AuNPs.21,28,30 By using a bidentate anchor, the overall graft density (the
number of anchors per unit area) will allow for more space on the surface of the AuNPs. With
the standard graft density of a monodentate thiol ligand being around 4-6 ligands/nm2, this
number would be halved with two anchor points sharing one ligand.33 This is hypothesized to
help improve the ROS generation, as the electrons are excited from the AuNPs, they will have
less obstructions to travel to their target destination. With The dithiol anchor coupled with the
polymer chains help to further stabilize – energetically and sterically respectively – the surface
of the nanoparticle and prevent it from aggregating as well as undergoing phagocytosis (being
engulfed by a cell and subsequently destroyed).34,21
The generation of ROS is a well-documented reaction that ultimately happens within the
electron transport chain of the body.35 Shown in Figure 2 is the Jablonski diagram showing the
process at which the electrons are excited and generate ROS. The tight regulation of ROS
generation is what allows for specific genes and other proteins to be regulated within the cell,
most notably with cell death; without regulation, the cell (overproduction of ROS) can turn
cancerous which is what aids in tumor growths. The ultimate method of removing cancer cells
is to cause oxidative stress which is the overproduction of ROS – in essence there needs to be
so much ROS generation that it inhibits everything related to cell growth.35 By adding in an
outside source of electrons, it will be possible to generate enough ROS to damage the tumor
growth without harming any healthy cells.
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Figure 2. General Jablonski diagram of how ROS generated through the electrons that are
excited through a light source.36,37 The light source excites the ground state electrons and as it
relaxes, it falls into the triplet excited state. The generated ROS is what triggers cell death.

This paper will focus on the overall percentage of ROS generated from the AuNPs
(diagram shown in Figure 3) that are exposed to the necessary excitation source which would
be an x-ray source. Due to ease of access to necessary equipment, this paper will focus on using
an ultraviolet light source to excite the electrons and quantifying the ROS generation through
UV/Vis spectrometry using a photosensitive dye, 1,3-diphenylisobenzofuran (DPBF).7,38 The
excitation of electrons to generate the superoxide anion react with DPBF to make 1,3dibenzoylbenzene (DBB) which does not share the same excitation wavelength as the starting
reagent.38 The more ROS that is generated, the less we see of the DPBF excitation peak in the
UV/Vis spectrum. The method outlined by Kohle et al. will be the method used for calculating
the percentage of ROS generated.6

iv.
Characterization Techniques
Multiple characterization techniques were used to analyze the necessary compounds
synthesized. The two most notable in the characterization techniques are matrix assisted laser
desorption ionization (MALDI) and 2D NMR. The former relies on having a laser ionize the
sample in question which has been pre-prepared in a matrix. The sample is desorbed from the
8

energy of the laser and then ionizes and travels to a mass analyzer – the amount of time it takes
to get to the mass analyzer is a determining factor in how the mass/molecular weight of the
sample is determined. The major difference between using GPC and MALDI for molecular
weight analysis, is MALDI allows for deeper understanding of the sample and the different
populations that lie within it. For example, a polymer sample may hold traces of unreacted
monomer, different populations of molecular weight (2000 MW vs 5000 MW), and the varying
distributions allow for a deeper analysis of what the sample is made of.
The latter technique mentioned, 2D NMR. In short, this technique overlays two different
spectrum together to make a 2D plot to compare the different peaks in both samples. This
allows for a deeper understanding of the sample as well as determine whether the ligand has
been bound to the surface of the gold nanoparticle. The main method of 2D NMR that will be
spoken to is nuclear Overhauser effect spectroscopy (NOESY) which will analyze the longdistance relationships between two spin nuclei which are far apart in distance. This will allow
for a closer look at how the protons are interacting before and after ligand exchange to help
confirm that ligands have bonded to the surface of the AuNPs.

Figure 3. A diagram of how the UV light will excite electrons at the surface of the gold
nanoparticle and generate ROS.

9

v.

Research Aims

This research aims to synthesize a dithiol-capped gold nanoparticle functionalized with PLGAtype polymer capping groups or ligands. This project aims to also characterize the products
synthesized and analyze the changes between the compounds before and after ROS exposure.
While UV light is the main light source spoken to in this paper, it will not be the ultimate source
of excitation if materials described herein were to be implemented in Cancer therapy. Longterm goals (past those of this thesis work) would be to investigate the treatment of cancer cells
through generation of reactive oxygen species by way of X-Ray irradiation. The use of UV light is
to set the method of characterizing ROS generation which will translate easily when using X-ray
as the source of ROS generation. By using these tailored AuNPs, we expect to better integrate
these AuNPs with additional PLGA-type precipitation methods that are common with PVA
which will improve solubility and stability within biological systems as well as be useful for the
integration of additional therapy agents (e.g. cis-platin, docetaxel, cyclophosphamide, etc.).39
This can achieve a treatment that can specifically target the cancerous site as well as more
efficiently remove the tumor without further damage to the host’s healthy cells. By using a
biocompatible polymer there will be little to no risk of toxicity from the AuNPs, allowing for
improved cancer treatment, less use of pharmaceutical drugs, and provide a more costeffective option of cancer treatment (the latter statement will not be explored within the scope
of this paper).

2. Syntheses and Results
This chapter will focus on the methods used to synthesize each of the necessary ligands
necessary for functionalized the gold nanoparticles as well as the synthesis of the AuNPs with
each of the previously stated ligands. These ligands and compounds are also listed in Figure 4.
The only ligand not synthesized but featured is chloroform-soluble poly(ethylene glycol) thiol
(ligand 3) capped gold nanoparticles provided by Bailey Klinger from Dr. Ying Bao’s research
group. A lab mate lead the synthesis of polymer 2 and ligand 2, using the methods outlined in
section bii and section bv.

10

This chapter also serves as a deeper look into the different building blocks of the ligands
and the different reagents used to conduct the studies. Full sample preparation methods for
characterization are listed in Appendix A.

Figure 4. List of the polymers and ligands synthesized and characterized. The polymers will be
used to create different polymer matrices for co-precipitation while the ligands will be used
during ligand exchange to functionalize the gold nanoparticles.

A. Introduction
The main driving force for using PDLLA based compounds within the scope of the project lies
within its durability as stated in Chapter 1A.i. While it is not a favorable characteristic for the
application of ROS generation in cancer therapies, it allows for a longer time frame to study the
materials and set the method needed before moving towards the PLGA based compounds.
There is less worry of the materials degrading over time if experiments are unable to be carried
out in a timely manner, ultimately leading to inaccurate results. PDLLA is also a simpler system
to analyze as there is only one monomer to consider in calculations while PLGA has two.
Both PLGA and PDLLA are synthesized by a ring-opening polymerization (ROP) of cyclic
monomers based on dimers of lactic acid or glycolic acid, or 3,6-Dimethyl-1,4-dioxane-2,5-dione
(racemate of S-S and R-R enantiomers: D-lactide and L-lactide) and 1,4-Dioxane-2,5-dione
(glycolide) respectively. The ROP is catalyzed by a Lewis acid such as tin(II) ethylhexanoate
[Sn(Oct)2] and initiated by an alcohol-containing molecule structure (see Scheme 1 and Scheme
2b and 2c). This method has been used to prepare well-defined homo- and block copolymers as
11

well as surface-anchored poly(L,L-lactic acid).8,19 For example, Olivier et al., and Lee et al.
recently demonstrated surface-initiated polymerization (SIP) with a planar gold substrate
functionalized with a hydroxyl group.19,20 Doing this allows for a more stable system overall and
better control over the polymers that are growing off the surface of the substrate. 8,19 The
method as outlined in Scheme 1 is the model that was used to synthesize PDLLA with a specific
dithiol end group as the initiator instead of 1,4-butanediol. The dithiolane end group of the
polymer will then be ligand exchanged for citrate moieties of gold nanoparticles to synthesize
the molecule shown in Scheme 3c.

Scheme 1. Ring opening polymerization using 1,4-butanediol as the initiator (a) of Poly(DLlactic acid) (PDLLA) with D,L-lactide monomer, and (b) of Poly(lactic-co-glycolid acid) (PLGA)
with D,L-lactide and glycolide monomers.
D,L-α-lipoic acid (LA) is esterified with ethylene glycol (EG) (2-hydroxyethyl-5-(1,2dithiolan-3-yl) pentanoate, compound 8, LA-EG) to afford for the ROP of monomer 2 or end
groups of monomers 2 and 4. The products, ligand 1 and ligand 2 are as shown in Scheme 2.
The

main

catalyst

for

the

reaction

was

dicyclohexylcarbodiimide

(DCC)

and

dimethylaminopyridine (DMAP). The use of LA-EG as a stabilizing ligand has been used in other
projects due to the dithiolane end group which allows for a more stable interaction between
the surface of the nanoparticle (e.g. gold, silver, and quantum dots) and the ligand. 10,28,40,41
LA (lipoic acid) and its ring opened derivative dihydrolipoic acid (DHLA) are both
biocompatible and have shown to have anti-inflammatory and antioxidant properties.41,42 With
LA being safe for consumption (most commonly as an oral vitamin) at the right levels, this
allows the entirety of the ligand to be safe for use in vivo. When LA is processed by the body
and broken down into DHLA, the body will excrete it through urine or other processes allowing
12

it pass safely through without toxicity concerns. It has also shown, through its antioxidant
properties, to be able to neutralize free radicals and ROS which can be beneficial in regulating
the amount of ROS that is generated in the body as well as during the ROS studies for this
project.42 While ethylene glycol, alone is highly toxic to humans and is used in anti-freeze and
other industrial chemicals, it is less toxic when polymerized into poly(ethylene glycol), only
being expelled through urine as the human body is unable to process it.43 By esterifying
ethylene glycol with lipoic acid, it should lessen the toxicity to be safe for use.

Scheme 2. The (a) esterification of D,L-α-Lipoic acid with ethylene glycol (EG) to synthesize
lipoic acid-ethylene glycol (LA-EG). Ring opening polymerization using LA-EG as the initiator (b)
of Poly(DL-lactic acid) (PDLLA) with D,L-lactide monomer, and (c) of Poly(lactic-co-glycolid acid)
(PLGA) with D,L-lactide and glycolide monomers.

Once the molecule as the one shown in Figure 5 has been made, the gold nanoparticles
will undergo X-ray irradiation to generate reactive oxygen species (ROS) in a targeted area. ROS,
in the general sense, are any type of radical oxygen species which include but are not limited to
(superoxide anions [·O2-] and hydroxide radicals [·OH-]). The electrons that are excited at the
surface of the AuNPs (photoelectrons and Auger electrons) will react with the surrounding
aqueous environment to produce oxygen radicals and hydrogen peroxide (which can be further
reduced or reacted) that can eliminate any cancer cells nearby. The use of ROS in cancer
treatment has shown to be impactful and effective (most notably in photodynamic therapy as
stated in chapter 1A.i) since the generation of ROS is a natural process in the electron transport
chain, however, ROS has also shown to aid in tumor growth.35,44,45 However, by having a high
13

enough concentration of ROS generated, it will only aid in tumor removal rather than tumor
growth. In practice, the therapeutic goal will be to generate ROS at a high enough percentage
while not damaging nearby cells which will be aided by the LA-EG initiator and the
concentration of functionalized gold nanoparticles that are co-precipitated into the polymer
surfactant.

Scheme 3. Reaction schemes highlighting the (a) the reduction of gold to Au0 with trisodium
citrate, and the ligand exchanges of Cit@AuNPs with (b) compound 13 and (c) compound 10.

To probe at the structural and molecular stability in PLGA/AuNP assemblies we apply a
UV-promoted pathway to generating ROS using UV light. To detect the amount of ROS
generated, DPBF will be used as the photosensitive agent. This molecule has an absorbance
around 410 nm6 (415 nm was the observed peak for this project) and will gradually decrease in
absorbance as it reacts with ROS – namely singlet oxygen to produce DBB which does not
absorb at the same wavelengths. After reacting with the singlet oxygen species, the furan ring
of DPBF opens to give way to two phenone groups. This change is what allows the ROS
generation to be tracked via UV-Vis. By taking linearizing the quotient between the initial and
final absorbance, a linear graph can be calculated and the slope will correlate to the ROS
generation for that sample.
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Figure 5. Overall molecule that we want to achieve; compound 15. Gold nanoparticle capped
with a dithiol ligand.

As stated in chapter 1, the solubility of the polymer capped nanoparticles in water is not
ideal and PVA will be used as a surfactant to allow for improved water dispersion. This will be
achieved through co-precipitating the AuNPs (dissolved in an organic solvent) into a solution of
PVA and polymer matrix with PVA as the surfactant. The solution is then sonicated to allow for
a full interaction between the organic and aqueous phases. Constant stirring throughout will
cause the PVA to enclose the particles in a nanosphere of polymers making them water
soluble.46 The now water soluble particles can be used for further experiments as well make
them compatible for use in vitro.
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Figure 6. Diagram showing the progression of the gold nanoparticles being co-precipitated in a
PVA/Polymer matrix to generate a polymer shell encasing several gold nanoparticles. Number
of particles shown, and relative thickness of shell are not to scale – only for visual purposes.
Another benefit of using PVA, a water-soluble polymer, allows for further uses of this
compound. As spoken to briefly in chapter 1, there have been many uses of polymer
nanoparticles being loaded with cancer drugs that are only soluble in organics. While cis-platin
is water soluble, the majority of cancer drugs available commercially or in production are
currently not which becomes a major hurdle for their production or use. 39 With compound 18
and 19 having a hydrophobic core, water-insoluble cancer drugs could be successfully loaded
and stabilized with the PVA/polymer surfactant to be used in other cancer therapies.
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B. Polymer Synthesis
i.
ROP of Poly(D,L-Lactic acid) with 1,4-butanediol initiator
Materials. D,L-lactide (DLL, 99%); 1,4-butanediol (BD, 99%); tin(II) ethylhexanoate (Sn(Oct)3),
95%); methanol (MeOH, wash grade); nanopure water; sodium chloride (NaCl); chloroform
(CHCl3, HPLC grade).
Methods. The ring opening polymerization (ROP) of D,L-lactide was done under a Schlenk line
and N2(gas). D,L-lactide monomer (15 mmol; 2.0 g), 1,4-butanediol (0.76 mmol; 68 mg), and
Sn(Oct)3 (28 mmol) were added to a multi-necked round bottom flask and set to reflux for 20
hours at 130°C.
Reaction was then quenched in an ice bath for several minutes while a mixture of 1:1 by
volume H2O:MeOH was prepared with sodium chloride (3.0 g) – this will be the precipitation
mixture. The precipitation mixture was then set to stir while the crude product was dissolved in
acetone (16 mL). Dropwise, the crude product was added to the precipitation mixture as it
stirred until all the product was added. The precipitation mixture was taken off stirring and left
to settle. The supernatant was decanted carefully, and the precipitate dissolved in chloroform
(16 mL). The organics were added to a separatory funnel with equal parts nanopure water. The
organic layer was washed for a total of three times, using fresh nanopure water; the organic
layer being collected after each wash. The collected organics was placed on a rotary evaporated
to remove excess solvent and purified polymer placed to dry in a vacuum oven overnight.
Resulting product is a white fluffy solid. Compound 3 (76% yield) was characterized via NMR
and FT-IR spectroscopy, and Gel Permeation Chromatography (GPC).
1H

NMR (500 MHz, CDCl3) δ 5.28 – 5.18 (m, 12H), 5.20 – 5.14 (m, 12H), 5.18 – 5.07 (m, 12H),

4.36 (q, J = 6.9 Hz, 2H), 4.16 (q, J = 3.9, 2.7 Hz, 4H), 1.63 – 1.53 (m, 106H), 1.53 (d, J = 10.6 Hz,
12H), 1.53 – 1.45 (m, 11H).
IR Data: 3520.9 (weak broad –OH), 2994.4 and 2946.1 (sharp sp3 –CH), 1744.2 (C=O ester peak)
GPC Data: MW = 4624 g/mol; Mn = 4070 g/mol; PDI = 1.1; further information is supplied in
Appendix A).
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ii.
ROP of Poly(lactic-co-glycolic acid) with 1,4-butanediol initiator
Materials. D,L-lactide (DLL, 99%); glycolide (GL, 98%); 1,4-butanediol (BD, 99%); tin(II)
ethylhexanoate (Sn(Oct)3), 95%); methanol (MeOH, wash grade); nanopure water; sodium
chloride (NaCl); chloroform (CHCl3, HPLC grade).
Methods. Compound 5 synthesis led by Liam La Belle. The method closely reflects the one
stated in section 2Aii but with the addition of the glycolide monomer (70:30 D,L-lactide to
glycolide mole ratio).
The purification procedure is similar as previously stated with only minor adjustments.
Once the crude product was set to precipitate, the mixture was left to stir overnight to allow
the polymer to fully interact with the methanol and water to precipitate. Once isolated,
compound 5 was then purified once more through a second precipitation. Compound 5 (35%
yield) was characterized via NMR and FT-IR spectroscopy, and GPC
1H

NMR (500 MHz, CDCl3) δ 5.22 (s, 29H), 4.76 (d, J = 46.5 Hz, 31H), 4.17 (s, 4H), 1.75 (s, 6H),

1.58 (s, 94H), 1.25 (s, 3H).
IR Data: 2995.0 and 2946.7 (weak but sharp sp3 -CH), 1753.0 (sharp C=O)
GPC Data: MW = 3662 g/mol; Mn = 2913 g/mol; PDI = 1.2

iii.

Esterification of dihydrolipoic acid-ethylene glycol (8)

Materials. D,L-α-Lipoic acid (DLLA, 99%); 4-dimethylaminopyridine (DMAP, 98%);

N,N’-

dicyclohexylcarbodiimide (DCC, 99%); dichlororomethane (DCM, wash grade); ethylene-glycol
(EG, 99%); celite; magnesium sulfate; methanol (MeOH, HPLC grade); ethyl acetate (EtOAc,
HPLC grade); magnesium sulfate (MgSO4). All chemicals were used as received.
Methods. Procedure is followed as outlined in Uyeda et.al.10 The only modification that was
made was replacing poly(ethylene glycol) with EG. Esterification was done under nitrogen gas.
EG (300 mmol), D,L-α-lipoic acid (30 mmol), DMAP (9 mmol) were all added to a round bottom
flask and dissolved in DCM (300 mL); solution should be clear with a yellow color A separate
solution of DCC (33 mmol) dissolved in DCM (20 mL) was prepared as contents of round bottom
flask was degassed for 20 min. After degassing, the solution was set to stir and DCC solution
was injected quickly into the flask. After injection, the flask was cooled with an ice bath for one
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hour before leaving to stir at room temperature for 20 hrs. The stirred solution gives rise to a
white precipitate during this time.
To purify, turn off stirring and filter through celite using a column or vacuum flask to
remove precipitate that formed in the solution (either method will work in removing the
precipitate. The collected crude organic product is then washed with brine three times; using
fresh brine after every wash and collecting the organic layer each time. The washed organics is
then dried over magnesium sulfate for a couple hours then filtered into a round bottom flask.
The excess solvent is then evaporated via rotary evaporator until only ~5-3mL is left;
attempting to leave too little solvent will result in an extremely sticky yellow solid that will
make it difficult to finish purification. The remaining product is then purified through flash
chromatography, using a 95:5 mixture of EtOAc:MeOH. Addition of EtOAc:MeOH straight to
product to attempt to ease pipetting into column will result in product separating prematurely.
The EtOAc:MeOH mixture was only added once all of the product has been added to the
column. A vibrant yellow band will pass through the column – this is the product going through
the column – which is collected and dried. Final product is a clear yellow semi-solid with a sticky
consistency. The final product is stored at ~4 °C until later required. Compound 8 (52% yield)
was characterized via NMR and FT-IR spectroscopy, and TLC.
1H

NMR (500 MHz, CDCl3) δ 4.25 – 4.19 (m, 4H), 3.87 – 3.80 (m, 3H), 3.62 – 3.53 (m, 2H), 3.23 –

3.07 (m, 4H), 2.51 – 2.42 (m, 1H), 2.38 (t, J = 7.5 Hz, 5H), 1.96 – 1.85 (m, 4H), 1.68 (s, 0H).
IR Data: 3427.9 (broad -OH), 2927.5 (sharp, sp3 -CH), 2857.1 (sharp, sp3 -CH), 1730.8 (sharp,
C=O)

iv.

Polymerization of Poly(D,L-Lactic acid) with compound 8 as initiator

Materials. D,L-lactide (DLL, 99%); Compound 8; tin(II) ethylhexanoate (Sn(Oct)3), 95%);
methanol (MeOH, wash grade); nanopure water; sodium chloride (NaCl); chloroform (CHCl3,
HPLC grade).
Methods. The method closely reflects the ones stated in sections 2Aii and 2Aiii with only a
change in the type of initiator that is used.
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After purification, the resulting polymer had a sticky slime consistency with a slight
yellow tint from the LA-EG initiator. The product was stored at ~0 °C until needed. Compound 9
(31% yield) was characterized via NMR and FT-IR spectroscopy, GPC and matrix assisted laser
desorption ionization (MALDI) shown in Appendix E.
1H

NMR (500 MHz, CDCl3) δ 5.36 – 5.08 (m, 284H), 5.06 (s, 5H), 5.03 (q, J = 6.7 Hz, 2H), 4.45 –

4.22 (m, 64H), 3.61 – 3.52 (m, 10H), 3.22 – 3.07 (m, 21H), 2.71 (s, 17H), 2.51 – 2.41 (m, 12H),
2.34 (td, J = 7.6, 1.6 Hz, 24H), 1.96 – 1.85 (m, 19H), 1.76 – 1.64 (m, 86H), 1.62 – 1.46 (m, 888H).
IR Data: 3427.9 (weak broad -OH), 2995.9 and 2942.9 (weak but sharp sp3 -CH), 1747.9 (sharp
C=O)
GPC Data: MW = 2382 g/mol; Mn = 1753 g/mol; PDI = 1.3

v.
ROP of Poly(lactic-co-glycolic acid) with LA-EG initiator
Materials. D,L-lactide (DLL, 99%); glycolide (GL, 98%); lipoic acid-ethylene glycol (LA-EG); tin(II)
ethylhexanoate (Sn(Oct)3), 95%); methanol (MeOH, wash grade); nanopure water; sodium
chloride (NaCl); chloroform (CHCl3, HPLC grade).
Methods. This method closely reflects the ones stated in the previous ROP procedures, using
the lactide and glycolide monomers to synthesize a co-polymer.
After purification, compound 10 was characterized and underwent another precipitation
purification procedure. The final resulting polymer became a clear and colorless solid with the
same sticky slime-like texture as stated in section 2Aiv. Compound 10 (Yield: 28%) was
characterized via NMR and FT-IR spectroscopy, GPC and MALDI (MW = 1569.8 g/mol).
1H

NMR (500 MHz, CDCl3) δ 5.35 – 5.07 (m, 100H), 4.93 – 4.56 (m, 94H), 4.32 – 4.15 (m, 7H),

3.57 (dt, J = 13.7, 6.3 Hz, 2H), 3.23 – 3.07 (m, 4H), 2.46 (dq, J = 12.7, 6.6 Hz, 2H), 2.34 (s, 3H),
1.91 (dq, J = 13.9, 6.9 Hz, 6H), 1.75 – 1.64 (m, 12H), 1.25 (s, 20H).
IR Data: 2999.3 and 2963.5 (weak but sharp sp3 -CH), 1748.5 (sharp C=O)
GPC Data: MW = 8695 g/mol; Mn = 3050 g/mol; PDI = 2.8

vi.
Attempted reduction of LA-EG initiated PDLLA with sodium borohydride
Materials. Ethanol (EtOH, 90 proof); nanopure water; sodium borohydride (NaBH4, 99%),
magnesium sulfate (MgSO4).
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Methods. The procedure outlined, closely follows that stated in Uyeda et.al.10 After the
synthesis and purification of compound 9, it was weighed out (10 mmol) and dissolved in a
mixture of ethanol and nanopure water (50mL, 1:4). NaBH4 (11 mmol)) was added and left to
stir for 60 minutes or until solution turned clear and colorless. The mixture was further diluted
with water (100 mL) and extracted with CHCl3 (3 x 75 mL). The combined organics were then
dried over MgSO4, filtered then purified via flash chromatography.
The following modifications were made to the procedure after several attempts at
isolating compound 9. During flash chromatography, several attempts at fractioning and using
thin layer chromatography (TLC) plates, it was determined that it compound 9 was eluting from
the column. The results from developing TLC plates with only crude product did not match the
results from the collected fractions after performing flash chromatography; the plates showed
no product at all. Based on this, the mole amount of NaBH4 was increased to a factor of 10-fold
to ensure reduction of the dithiol ring. The rest of the purification, save the flash
chromatography was kept as previously stated. The final product, a clear and colorless residue
(dihydrolipoic acid-ethylene glycol-PDLLA) was characterized via NMR spectroscopy. The
resulting spectrum indicated the decrease in several peaks which was indicative of loss of
polymer or the degradation of the polymer chain (Appendix D).

vii.
Attempted reduction of LA-EG initiated PDLLA with tri-n-butylphosphine
Materials. Compound 9, tetrahydrofuran (THF, HPLC grade), tri-n-butylphosphine (Bu3P, 94%),
hydrogen chloride, pure 1N solution in diethyl ether, anhydrous ethyl ether (99%)
Methods. The method outlined is based off the procedure stated by Karlarickal et.al.47
After the synthesis of compound 9, it was weighed out (0.020 g) and dissolved in THF (17
mL) in a 50-mL round bottom flask and purged with N2(gas) for several minutes while stirring.
Then Bu3P (1.7mL) was injected into the flask and left to stir overnight.
To purify, acidified diethyl ether (1:1 precipitation mixture to reaction mixture), was
chilled in a N2(gas) purged Erlenmeyer flask. The reaction mixture was then added slowly to the
Erlenmeyer flask via syringe needle. The mixture turned cloudy white during the addition but
slowly turned clear and colorless. Further acidified diethyl ether was added to return the
mixture to its original cloudiness before allowing to settle for an hour. The supernatant was
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decanted, and the precipitate dried via rotary evaporator and vacuum drying overnight. The
resulting product, a clear and colorless liquid was characterized via NMR spectroscopy
(Appendix D).

C. Nanoparticle Syntheses
i.

Synthesis of citrate-capped gold nanoparticles (AuNPs)

Materials. Trisodium citrate (Na3Cit, 99%); hydrogen tetrachloroaurate dihyrdrate (HAuCl4,
99%); nanopure water.
Method. Procedure shown here was based on the Brust et.al. method.9 Synthesis of citrate
capped AuNPs (Cit@AuNPs) was done connected to a Schlenk line under N2(gas) with a
waterless condenser. In a multi-necked round bottom flask sodium citrate (2.2 mM) was
dissolved in nanopure water (150 mL). The flask was then set in oil bath until boiling. While
waiting for solvent to boil, two separate solutions (3mL each) were prepared; (I) aqueous
HAuCl4 (60 mM) and (II) aqueous Na3Cit (60 mM). Once solution in flask was boiling, 1mL of (I)
was injected into the flask. After 10min the solution turned from clear and colorless to a dark
grey then to a deep wine-red color; this is the initial growth of the AuNPs. After the solution in
the flask changed color, another 1mL injection of (II) was administered. There was a waiting
period of 2min before injecting another 1mL of (I); this concludes the first seeding after the
initial growth. For subsequent growths, a period of 30min must pass (always after (I) is added)
before the next round of seeded growth. The typical number of growth cycles is 2. The wine-red
color deepens slightly with each subsequent seeded growth cycles.
After removing flask from oil bath and allowing contents to cool, the AuNPs are then put
into 50mL tubes and placed into fridge to be stored until use. Purification of Cit@AuNPs
involves adding necessary amount to centrifuge tube and spinning at 13krpm for 30min. Clear
supernatant was decanted and fresh nanopure water was added. This is repeated as many
times as necessary (typically up to three times) and followed by storage in nanopure water at
~4 °C. Compound 12 was analyzed via dynamic light scattering (DLS), UV-Vis spectroscopy, and
scanning transmission electron microscopy (STEM).
DLS: 32.1 ± 0.036 nm (diameter); PDI = 0.285 (further information is listed in Appendix A)
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UV-Vis: 5.63x10-9 M (3.72x1012 particles/mL); λmax = 523 nm
STEM: DAuNP = 20.25 ± 0.023; Standard Deviation = 2.34 nm (further information is listed in
Appendix A)

ii.

Biphasic ligand exchange of Cit@AuNPs with DEP polymer

Materials. Compound 12; Compound 12, toluene (HPLC grade), acetone (wash grade)
Method. Procedure outlined was based on procedure described by Ranoszek-Soliwoda et.al.48
First, Cit@AuNPs (20mL) was purified to necessary specifications and placed into a 50mL
storage tube. Then ligand 1 (0.01 wt% toluene solution) was weighed into a separate clean
glass vial and dissolved in toluene (10mL). Once fully dissolved, the toluene solution was added
to the 50mL storage tube; to help facilitate the phase transfer, acetone (10mL) was added as
well. Then the tube was shaken vigorously for 30min; when left to rest for a couple minutes,
the lower (aqueous layer) and upper layer (organic layer) began to separate, and the lower
layer turned to a soft purple color and a metallic sheen could be seen surrounding the aqueous
layer. The storage tube was allowed to rest overnight in the refrigerator.
The lower aqueous layer was purified through centrifugation. The lower layer was
sonicated for 30min before pipetted into 2mL centrifuge tubes; the tubes were spun at 13krpm
for 30min. After centrifugation, a dark pellet had collected at the bottom of the tube and a
milky white substance remained at the top while the supernatant remained clear and colorless.
The supernatant was decanted carefully using a needle and syringe, being careful not to disturb
the milky substance or the pellet. Being careful of the pellet, the supernatant was decanted and
then fresh CHCl3 was added. Sonication was used to help disperse any other particles before
spinning again at 13krpm for 30min. CHCl3 was the final solvent that the particles were stored
in.
The same procedure was performed to synthesize compound 15, with the only change
made to the type of ligand used (ligand 2 instead of ligand 1). Compound 14 and 15 was
characterized via UV-Vis and NMR spectroscopy, DLS, and STEM.
Compound 14
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1H

NMR (500 MHz, CDCl3) δ 5.46 (s, 3H), 5.28 (s, 2H), 4.62 (d, J = 39.7 Hz, 3H), 3.20 (s, 2H), 2.31

– 2.24 (m, 1H), 2.17 (d, J = 7.5 Hz, 2H), 2.09 (t, J = 7.6 Hz, 1H), 1.94 (q, J = 6.5 Hz, 5H), 1.89 (s,
7H), 1.50 (s, 18H), 1.19 (s, 83H), 0.74 (s, 76H).
DLS: 175 ± 0.59 nm; PDI = 0.466
UV-Vis: 1.10x10-9 M (7.27x1011 particles/mL); λmax = 528 nm
STEM: DAuNP = 17.62 ± 0.02 nm; Standard Deviation = 2.02 nm
Compound 15
DLS: 230.7 ± 0.31 nm; PDI = 0.168
UV-Vis: 2.01x10-9 M (1.37x1012 particles/mL); λmax = 527 nm
STEM: DAuNP = 62.9 ± 0.24 nm; Standard Deviation = 23.5 nm

iii.
method
Materials. Poly(vinyl alcohol) (PVA cold water soluble, 99%); compound 14, compound 15,
polymer 1, polymer 2, nanopure water.
Method. This method follows the procedure outlined in Andreu et.al.46 PVA is dissolved in
nanopure water (50mL) – typically requiring sonication and/or stirring overnight. The
DEP@AuNPs (2.5mL; 1.10x10-9 M) were purified via centrifugation and stored in CHCl3 as the
organic solvent until ready. The necessary polymer (either PDLLA or PLGA) is dissolved in the
prepared DEP@AuNP solution and chilled at 0 °C until needed. The DEP@AuNPs/Polymer
solution was prepared the day of the experiment.
An aliquot of the PVA solution (15mL) was removed and placed into a clean 20-mL
scintillation vial. The vial was put into an ice bath and set to stir. A sonicator probe was placed
into the vial to prepare for the next steps. While the solution was spinning vigorously, the
DEP@AuNPs/Polymer (either PDLLA or PLGA) solution was very slowly and carefully pipetted
into the bottom of the vial until the entire solution was gone.
The same procedure was used to co-precipitate compound 19 with swapping compound
14 with compound 15 and polymer 1 with polymer 2. Compound 18, and compound 19 were
characterized via UV-Vis, DLS and STEM.
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Compound 18
DLS: 2.7x104 ± 5.2; PDI = 0.314
UV-Vis: 1.76x10-10 M (1.16x1011 particles/mL); λmax = 528 nm
STEM: DAuNP = 240 ± 12 nm (based on 15 measured populations); Standard Deviation = 174.75
nm
Compound 19
DLS: 1.4x105 ± 179 nm; PDI = 0.152
UV-Vis: 8.10x10-11 M (5.37x1010 particles/mL); λmax = 527 nm
STEM:

3. Discussion and Application
A. Polymer Results
The polymers synthesized in this paper fall into two categories: 1) polymers initiated with BD to
be used at a polymer matrix for co-precipitation and 2) polymers initiated with LA-EG for use as
ligands to functionalize the surface of the AuNPs.

i.
1,4-butanediol initiated polymers
Based on the NMR spectra collected of the reagents, it was concluded that polymer 1 was
successfully synthesized with minimal unreacted monomer present within the purified product
(80% yield, 90% purity). As shown in Figure 7, the peaks at 5.04 ppm (-CH2) and 1.71 ppm (CH3)
correspond to the unreacted monomer (-CH bond) that was not isolated during purification
while the peak at 5.20 ppm corresponds to the -CH main group in PDLLA polymer 1. The peak at
5.20 ppm is higher in intensity than that at 5.04 ppm. Their integrals also show a 75:1
(polymer:monomer) indicating that there is a majority of polymer within the sample.
Molecular weight was determined via NMR (MW = 3173.3 g/mol), and GPC. Using 1HNMR integration, of groups associated with the initiator (BD) and that for repeats in PDLLA are
used for molecular weight calculation. The signal at 4.16 ppm corresponds to the protons
adjacent to the oxygen in the BD central unit. The signal at 1.57 ppm corresponds to the
protons of the methyl side-chain of PDLLA. By multiplying the quotient of the normalized 4.16
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ppm and 1.57 ppm integrals by 0.33. This product is divided by 2 to obtain the number of
repeat units per lactide ring (~20 repeat units).

Figure 7. NMR spectrum of polymer 1.
While a similar method was used to calculate the molecular weight of compound 5, the
only modification that needed to be made was regarding the addition of the glycolide content.
Otherwise, the same NMR calculations were made to determine the molecular weight of
polymer 2. This was further confirmed by GPC (MW = 3662 g/mol). While the MALDI (MW =
1541.8 g/mol) data shows a difference in molecular weight, this could be due to any side
products made within the reaction that were not purified or a difference in how the glycolide
and lactide monomers interacted and polymerized together. The other calculation done was to
determine the true ratio between the glycolide and lactide units which came out to be 65:35,
which is very close to the targeted 70:30 ratio.
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Figure 8. NMR Spectrum of polymer 2.

ii.
LA-EG initiated polymers
Using the method outlined by Uyeda et.al10, the initiator was characterized by NMR and
compared to the NMR spectral data provided by the literature (Appendix C). The two main
peaks that were analyzed were the presence or absence of the alcohol -OH stretch in the 3000
cm-1 regions as well as the shift in the C=O peak between each ligand and the starting molecule
(LA). As shown in Figure 9, there is a broad but jagged peak which indicates the presence of a
carboxylic acid which is consistent with the Lewis structure of compound 6. This peak smooths
out and is a lot broader as it undergoes esterification; Figure 9 (LA-EG, compound 8), the bell
curve at 3427.9 cm-1 is a very clear alcohol peak consistent with the alcohol terminated EG.
Along with the spectral data provided in (Appendix C), Figure 10 and literature10, this provided
confidence in using it as the initiator in the following reactions.
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Figure 9. IR spectra comparing the monomers (left), (a) DL-lipoic acid, (b) glycolide and (c) DLlactide to their polymers (right), (d) ligand 2, (e) PLGA polymer 2, (f) ligand 1, and (g) PDLLA
polymer 1.
The overall functional groups of each ligand were determined via FT-IR spectroscopy.
Starting with (Figure 9f) ligand 1, there was a weak but broad peak at 3427.9 cm -1 which shows
a hydroxyl group; the weakness in its intensity is explained it is low abundance in comparison
with the rest of the polymer chain. The other characteristic peak is the C=O ester peak at
1747.9 cm-1. This was a sharp peak which is similar in shift to its monomer, DLL (1751.3 cm-1)
but has shifted to a lower wavenumber which is due to the large number of electron
withdrawing R groups, causing the C=O bond to shorten and lowering the frequency. 47,49
The molecular weight was determined with several different techniques. The first was
calculating through the integrations in the NMR spectrum. This calculation follows what was
stated previously for the BD-initiated polymers with the modification that there is only one
initiator site rather than two. This was also confirmed through GPC (MW = 2382 g/mol;
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Retention Volume = 8.927). This coupled with the IR data confirm that PDLLA polymer 1 was
successfully polymerized and purified.
Moving to polymer 2, the main difference was factoring in the glycolic acid portion of
the co-polymer. The same techniques were used to analyze polymer 2 as were used in with
polymer 1. As shown in Appendix B, there is a single peak corresponding to the CH2 groups on
the ring around 4.95 ppm. This singlet peak turns into a multiplet peak after polymerization
which his indicative of multiple CH signals that have polymerized.

Figure 10. NMR spectra comparing (above) D,L-α-lipoic acid and (below) LA-EG. Rf = 0.3 from
flash chromatography.
Using different techniques, the molecular weight of the polymer was determined as
well. Based on NMR – with the method described when calculating molecular weight for the BD
initiated polymers were adjusted for the LA-EG initiated ligands – the molecular weight was
concluded as 2217 MW; this molecular weight was confirmed with GPC (MW = 2382; Retention
Volume = 8.9). By using MALDI, the molecular weight was determined to be 1569.8 DA
(Appendix E). The discrepancy in the molecular weight values may be due to how Ligand 1
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ionizes when performing MALDI-TOF analysis. Having an end group initiator may have cause it
to cleave from the rest of the polymer which can impact the overall molecular weight of the
molecule. However, while analyzing the molecular weight gaps between peaks, the difference
between them was calculated to be roughly 144 DA; this helped to confirm the monomer units
on the polymer chain.

Figure 11. Spectral data for compound 13 including NMR.
The differing distributions on the MALDI spectrum show that there are different
distributions within the spectrum. As seen in Appendix E, there are three major populations
that make up more than half the sample. By using the software, PolyTools, it is possible to
determine the best-case scenario for each of the populations. By looking at different scenarios,
the varying distributions can be accounted for in the data. When given certain constraints, the
software will calculate a residual value which corresponds to the amount of mass that is not
accounted for within the molecular weight. The second most prominent scenario is the one that
will be focused on. When accounting for the mass of the initiator and the mass of the end
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group (just a single hydrogen) and the cations that are within the matrix (namely sodium), the
data shows a very low residual number which makes it the most likely that compound 9 is one
of the majority distributions. This gives confidence that the compound was synthesized.
The most prominent distribution shows the most likely scenario being a simple
hydrogen end group with no initiator. This could be possible if the sample underwent hydrolysis
either within the instrument when exposed to the laser source or there may be sample
degradation over time.

Figure 12. NMR spectrum of ligand 2.
Thermogravimetric analysis (TGA) utilizes heat to determine the heat at which different
bonds in specific compounds burn away. By taking the weight of the sample that is being
analyzed, the amount of weight loss from the heating is tracked over time at different
temperatures. By analyzing the free ligands and the functionalized gold nanoparticles, the mass
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loss events should be different as the bond interactions will differ. This analysis will help to
determine whether the desired polymer has been grafted to the surface.
The TGA graph of the ligands are placed in comparison to the graphs of the starting
materials and the polymers. These show the different mass loss events not only within the
thermograph but within the first derivative of the graph as well. Using Figure 13b and 13c the
two mass loss events that are shown correspond to the two peaks that are seen in Figure 13a. It
is another sign that ligand 1 has an LA-EG initiator.

Figure 13. TGA thermographs of (a) DEP@AuNPs, (b) compound 6 and (c) polymer 1.

B. Gold Nanoparticle Results
The use of AuNPs in medicine has been well documented to aid in drug loading, imaging, and
other medical uses. By using functionalized AuNPs, we can use them for ROS generation to
combat cancer cells. The citrate capped gold was synthesized using a gold salt (HAuCl4) and a
reducing agent (Na3Cit) to reduce the gold into Au0. This also allows the citrate to act as a ligand
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and stabilize the surface of the gold nanoparticle, turning it into a spherical shape.28,50 These
particles are then prepared to undergo biphasic ligand exchange via centrifugation to purify;
with the citrate capped gold in an aqueous solution and the polymer ligand dissolved in an
organic phase. The resulting particle is dissolved with a polymer matrix and co-precipitated into
a PVA solution to generate the nanoprecipitate material.
While ROS is not limited to the superoxide species, this will be the one that will be
studied as its generation is what leads to DPBF reacting to generate DBB. 6,38,51This is tracked via
UV-Vis as the peak that shows at 415 nm decreases the more it reacts with superoxide. It is also
marked by a change in color in the solution – DPBF is a vibrant yellow solid and continues to
hold that color when dissolved in organic solvents. As it reacts with superoxide, it slowly turns
into a fainter and less vibrant yellow until it turns completely clear and colorless when not
mixed with anything else. This makes it an ideal photosensitizer when conducting the ROS
studies.

i.
Citrate capped gold nanoparticles
The main characterization of all the gold nanoparticles lies in DLS, UV-Vis, and STEM. The
starting point for all the ligand exchanged particles starts with the citrate capped gold. These
particles were analyzed using the three techniques listed and the results are shown in Figure
14.
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Figure 14. Characterization of cit@AuNPs via (a) UV-Vis spectra with an absorbance at 525 nm
as well as (b, c) STEM images of citrate capped particles (20 nm diameter; STD = 2nm) using the
dark field detector. DLS sizing information shows particles with an average monomodal
diameter size of 20 nm.
Looking at the UV-Vis spectrum in Figure 14a, the surface plasmon resonance shows a
peak at 525 nm indicating a 20 nm diameter particle, which is consistent with a current data
available in literature.9,52 While in Table I, the listed size of Cit@AuNPs are listed as 32.1 nm,
this is to be expected as sizing by dynamic light scattering (DLS) focused on the hydrodynamic
radius of the particle including contributions from bound ligands and/or ions which may
account for the slight discrepancy between the DLS and STEM size measurements. The average
size of the Cit@AuNPs were 20 nm (averaged from the sizes of 100 collected particles). The
collected images show uniformly sizes and dispersed gold nanoparticles with no obvious signs
of aggregation. Visually, the particles also showed a clear wine-red color showing stability and
no visual signs of precipitated solids which would indicate aggregation. These particles were
used for the next step of ligand exchange.

ii.
Polymer capped gold nanoparticles
The main characterization of the polymer capped AuNPs was UV-Vis to determine the plasmon
resonance of the gold particles. DLS was used to determine the overall size of the entire particle
while STEM imaging was applied to possibly to observe the surface differences between citrate
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capped and polymer capped particles. When available (at high enough concentrations), NMR
was also used to detect any chemical shifts to determine the bonding of the polymer to the
gold surface.
Starting with UV-Vis, the peaks shown in Figure 15 are all in the 520 nm range which
indicates that the overall gold particle has not increased or decreased significantly in size
compared to its citrate capped precursor. This is important to note as the ligand exchange did
not alter the size of the AuNPs or cause them to aggregate significantly meaning the particles
are stable with the new ligand. This information coupled with the increased DLS sizing of 120
nm (see Table I) shows that there are larger particles within solution, but they are not due to
the aggregation of the AuNPs. Visually, the particles are stable in solution and show a clear pink
to light purple color. The particles are stable in solution even after being stored in the fridge
and show no signs of aggregation (visible black specks in the solution).
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Figure 15. UV-Vis spectra of each species of AuNPs with (a) showing the functionalized gold
including PEG capped particles from Dr. Bao’s group and (b) the co-precipitated polymer
capped gold. STEM images of (ai) compound 14, and (bi) compound 18 before and (aii, and bii
respectively) after ROS exposure.
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Reported in Figure 15ai, aii and 15bi, bii, are STEM images of compound 14 and
compound 18 prior to and following the application for UV promoted ROS generation. Prior to
ROS, compound 14 shows well dispersed and uniformly shaped particles (AVG diameter size =
17.62 ± 0.002 nm). This change after UV light and ROS generation, as the particles are now less
uniformly shaped and show visible aggregation in the sample (AVG diameter size = 43.6 ± 0.11
nm). The change in the functionality of the particles is also confirmed by the peak broadening
and shifting shown in Figure 16. Another comparison that can be made which helps to support
functionality is the spacing between the particles of compound 14 compared to compound 12
(in Figure 15). There are more populations of closely packed particles for compound 12 while
there are more singularly spaced particles for compound 14 (Figure 15ai). There is an average
length of 105 ± 1.0 nm between the particles while it is significantly shorter for compound 12.
Looking closer at compound 18 (Figure 15bi) there are a couple populations of particles
clumped together. There is a grey line that appears to be a grey halo that encompasses each
AuNPs which could indicate that there is polymer surround each particle. This shows that the
co-precipitation was successful in encompassing the particles (average number of particles per
clump is roughly 6/clump from ten measured populations).
By utilizing NOESY as shown in Figure 16, a comparison between the free ligand
(compound 9 on the left) and the functionalized AuNPs (compound 14 on the right) can be
made. This technique allows characterization of the long-range effect between two protons
rather than the neighboring proton as with 1D NMR. For small molecules, NOE cross peaks have
opposite phase to peaks found along the diagonal whereas signals for molecules bound to
surfaces or larger particles exhibit matched phase to those positioned on the diagonal. The two
main points of interest lie in the ~5.0 ppm region where the CH closest to the oxygen shows a
peak in the NOESY spectrum but is missing when looking at compound 14. This coupled with the
peak showing at ~1.0 ppm (the methyl groups on the backbone) do not have a peak in the free
ligand but are visible when it is bound. This shows that the surface of the AuNP is now able to
interact with the ends of the polymer where there was no long range interaction at all when it
was still a free ligand.
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Figure 16. NOESY 2D NMR showing the main points of interest circled in teal and pink where
the dithiolane is no longer able to interact with the rest of the ligand protons. The blue peaks
indicate negative correlation while the red indicates positive.

Further characterization using NMR (Figure 17) shows the comparison of compound 14
prior and following UV light and ROS generation. The spectrum below shows an increase in
peaks between 7.0 ppm and 7.8 ppm which is indicative of 1,2-dibenzoylbenzene (the doublet
at 7.8 ppm is characteristic of DBB while a multiplet is indicative of DPBF).53 This is an indicator
that ROS were generated and interacted with DPBF to open its furan ring. Another sign of
changes in functionality can be seen through a quartet at 3.7 ppm which is characteristic of a
solitary lactic acid unit and points towards possible polymer degradation following ROS
generation.54 This can also be seen through the peak shifting in Figure 18c as it shifts and
broadens towards larger wavelengths.
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Figure 17. 1H NMR spectra of compound 14 before (above) and after (below) UV light exposure.

iii.
Co-precipitated polymer capped gold nanoparticles
The results of the nano-precipitated gold are shown mostly within the DLS diameter sizing data
(Table I). The final product was a clear and colorless solution and when centrifuged, showed a
white pellet with light purple spots within it which indicates gold nanoparticles. The initial size
differences between the functionalized gold particles (Compound 14 and 15) and the nanoprecipitated gold (Compound 18 and 19), show that there was a visible change in diameter size
after the co-precipitation. This coupled with the visual changes indicate that the coprecipitation was successful.
Table I. DLS sizing – following UV-promoted ROS generation with λ = 254 nm and 300 nm
Hydrodynamic Diameter sizing (nm)
254 nm Emission 300 nm Emission
Name
Prior to ROS
After
After
Cit@AuNP (Compound 12)
32.1 ± 0.036
86.6 ± 0.25
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DEP@AuNPs (Compound 14)
175 ± 0.59
DEPLGA@AuNPs (Compound 15)
230.7 ± 0.31
PEG@AuNPs (Compound 17)
153.2 ± 0.99
PVA/PDLLA-DEP@AuNPs
2.7x104 ± 5.2
(Compound 18)
PVA/PLGA-DEPLGA@AuNPs
1.4x105 ± 179
(Compound 19)
All particles were measured according to 70 replicates.

5.2x104 ± 54.9
3.6x104 ± 35.5
118.3 ± 1.0

2.4x104 ± 29
1.7x104 ± 5.3

1.2x104 ± 80.1

2.7x103 ± 5.5
1.1x104 ± 220

Comparing the different sizes between before and after UV light exposure, the particles
tended to grow larger in sizes indicating aggregation and loss of particle functionality. The one
compound that did not follow this trend was the PEG thiol functionalized gold particles which
remained a uniform size despite being exposed to UV light. While avoiding aggregation allows
the particles to be used in the most optimal way, having the increase in particle size is arguable
beneficial for this project. Larger particles that are processed by the liver are more likely to be
passed through the body as waste rather than continue circulating where they could pass
through different membranes and accumulate.55 The smaller particles may stay within the
system, causing toxicity concerns in vivo especially if they still retain functionality – any
additional X-ray radiation may cause damage to healthy cells where the particles have
accumulated if not expelled.

C. ROS Results
The ROS generation methods that are described are based off the method used by Kohle et. al.6
ROS were generated using the RMR-600 Rayonet UV reactor in conjunction with two different
UV lamps which emit at different emissions and ranges. The first lamp used emitted at 254 nm
(full width half max = 10 nm) and at 300 nm (full width half max = ~110 nm). Using two different
bulbs can highlight the best range at which to excite the particles to increase their efficacy. The
254 nm emitting light bulbs only emit over a small range of the UV spectrum making them a
high energy and targeted light source that will generate ROS while the other has slightly less
energy but can emit at a wider range which covers the 415 nm wavelength were DPBF absorbs
at. By having light bulbs that emit at a wider range, it will allow for more of the compound to be
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excited/absorb the UV light allowing for increased ROS generation and/or the ideal conditions
for optimizing ROS generation.
i.
Methylene Blue Standards
Materials. Methylene blue (MB); 1,4-diphenylisobenzofuran (DPBF, 97%), ethanol (EtOH, 90
proof). All chemicals were used as received.
Method. The method described was based on procedure established by Żamojć et.al.6,7,56
Before performing experiment, solutions of DPBF (1.39x10-4 M) and MB (1.04x10-2 M)
were prepared beforehand using ethanol as the solvent – for experiment with gold
nanoparticles, CHCl3 and DMF were also tested. To determine the best concentration of MB to
begin experimentation, a serial dilution was performed while collecting UV/Vis spectra of each
dilution. It was determined that (1.15x10-6 M) was the best concentration to start when
performing ROS experiments.
Using a quartz glass microcuvette, it was filled with MB (1mL) and DPBF (0.5mL), and
then placed into the UV/Vis spectrophotometer to take an initial spectrum. The cuvette was
then methodically exposed to UV light using a UV light box for intervals of 5sec (length of 20
sec) then intervals 10 sec (until peak at 415 nm is close to baseline). After each exposure, a
spectrum was taken with the spectrophotometer. This method was repeated for DMF and
CHCl3 as the solvent and both yielded similar results as the ethanol. The particles were assessed
for ROS generation via UV-Vis spectroscopy. The spectrum shown in Figure 14 shows two peaks
which correspond to DPBF (415 nm) and MB (610nm) respectively.
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Figure 18. UV-Vis spectra of ROS study using MB (610 nm) and DPBF (415 nm) using (a) 254 nm
in ethanol and (b) 300 nm wavelength in DMF, UV light bulbs. And ROS studies of compound 14
using (c) 254 nm and (d) 300 nm light in CHCl3 with a highlight on the shift of the 529 nm peak
due to UV light exposure.
The most obvious indicator of ROS generation is the decrease in intensity of the peak at
415 nm, and therefore concentration of DPBF within the solution. The solution made was light
blue and clear in color and after the addition of DPBF, turned a light shade of green. As the
solution was repeatedly exposed to UV light, the color of the solution slowly returned to a light
blue color (a good indicator that there is no residual DPBF left in solution, is the lack of yellow
color in the solution). The conversion of DPBF to DBB slowly causes the peak at 415 nm to
decrease as DBB does not have an absorbance within the range being analyzed.
To determine the quantum yield of the ROS generated, the maximum peak height at
415 nm at each interval – with zero seconds of exposure being the initial absorbance (A0) and
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each subsequent data point being the final absorbance (A) – the natural log of (A0/A) was
calculated. The plotted data points were fitted according to a linear regression and the slope
(MMB) used in equation 1, where (𝜑sample)x100% is the Quantum Yield of the sample, 𝜑MB (0.52)
is a constant based of MB values in ethanol,6 mMB is the slope of the MB standard, and msample is
the slope of the sample – namely the gold particles being analyzed. For simplicity, the slope will
be referred to as Absorbance/sec (A/sec) to avoid any confusion over the y-axis value.

𝜑∆ = 𝜑𝑀𝐵

1)

𝑚𝑠𝑎𝑚𝑝𝑙𝑒
𝑚𝑀𝐵

The slope found in this MB ROS study was 0.12662 A/sec and will be used for all
calculations regarding quantum yield. When necessary, the solvent was changed to either DMF
or CHCl3 as DPBF is only soluble in organic solvents.

ii.
ROS generation with Cit@AuNPs and functionalized AuNPs
Materials. Compound 12; 1,4-diphenylisobenzofuran (DPBF; [purity]); N,N’-dimethylformamide
(DMF, HPLC grade); chloroform (CHCl3; HPLC grade). All chemicals were used as received.
Method. This method follows what was outlined in section 2C.i but substituting MB with either
Cit@AuNPs or DEP@AuNPs respectively. In the case of Cit@AuNPs, the solvent used was DMF
to as the particles were not soluble in CHCl3 and DEP@AuNPs were dissolved in CHCl3.
Results. The main characterization was UV-Vis to study the amount of ROS generation within
the samples while STEM imaging was used to observe the effects of repeated exposure to UV
light. Several compounds were analyzed including, compounds 14, 15, 17 (PEGSH@AuNPs), 18,
and 19.
The ROS generation is shown visually in Figure 19 and summarized in Table II. The trend
shows that the quantum yield (QY) of the particles increases as their slope increases. With the
highest slope being for the DEP@AuNPs, this shows that it has the highest ability to generate
ROS within the sample (254 nm = 20% and 300 nm = 28%). However, as shown in Figure 18b,
there is no further ability to generate ROS as the DPBF peak at 415 nm has flattened out after 1
minute of UV light exposure. This is the same the PEG@AuNPs. While their ability to generate
ROS is high, their ability to continuously generate it is lower.
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Figure 19. ROS generation studies via UV light using a (a) 254 nm wavelength source and (b)
300 nm wavelength source done over three replicates.
When comparing between compounds 14, and 15, there is a clear difference between
them and compounds 18 and 19. While 14/15 show a strong ROS generation and a high QY,
they do not show any further ability to generate ROS after 1 minute of exposure. While a high
QY is desirable, it is also beneficial to achieve a high but sustained ROS generation to combat
cancer cells.6,45
The plateau of the graphs is indicative of the lack of the DPBF in solution as well as the
lack of ability of the gold nanoparticles to generate further electrons to generate ROS. This is
backed up by the UV-Vis spectra shown in Figure 18b and 18d. The plasmon resonance shifts
from a well-defined peak around 520 nm, to a very broad peak shifting towards 600 nm the
longer it is exposed to UV light and the decrease in absorbance. This can be indicative of the
gold particles beginning to aggregate due to the ligands becoming unstable on the surface.
While the lack of ligands impacts the stability, the increase in size is something that is desirable.
As the particles irradiate and lose their function, the ligands and polymers will be processed by
the body and the larger particles will pass through the liver to turn into waste as stated in
Chapter 3 Section Biii.55 A good observation to note is that the moment the DEP@AuNPs graph
in Figure 19b begins to level off at ~40 seconds (no more ROS is being generated), is the same
time that the UV-Vis graph begins to shift and broaden out in Figure 18d (aggregation).
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This is the reasoning why the citrate gold (compound 12), while it can generate ROS and
is already water soluble, would not be the optimal compound to use for these studies. At 20 nm
in size, they are small enough to not be processed by the liver and the ligands, when not bound
to gold, may cause concerns for cytotoxicity [reference].28,57 The other reason would be the lack
of flexibility in the citrate gold. Since they are water soluble, they cannot be used in tandem
with hydrophobic drugs – hydrophobic cancer drugs cannot be loaded into water soluble citrate
gold to be used in targeted cancer treatment.
Table II. ROS Quantum Yield Values – 254 nm emission
ROS Values
Compound Name
Cit@AuNP (Compound 12)
DEP@AuNPs (Compound 14)
DEPLGA@AuNPs (Compound 15)
PEG@AuNPs (Compound 17)
PVA/PDLLA-DEP@AuNPs
(Compound 18)
PVA/PLGA-DEPLGA@AuNPs
(Compound 19)

Slope (A/sec)
4.69x10-3 ± 0.0004
5.54x10-2 ± 0.004
1.15x10-2 ± 0.003
3.95x10-2 ± 0.004

φsample
0.0173
0.204
0.0427
0.1456

QY%
1.73% ± 2.2x10-2+
20.4% ± 4.0x10-2
4.27% ± 4.1x10-4
14.56% ± 4.1x10-3

1.18x10-2 ± 0.002

0.0433

4.33% ± 3.4x10-4

N/A

Table III. ROS Quantum Yield Values – 300 nm emission
ROS Values
Compound Name
Cit@AuNP (Compound 12)
DEP@AuNPs (Compound 14)
DEPLGA@AuNPs (Compound 15)
PEG@AuNPs (Compound 17)
PVA/PDLLA-DEP@AuNPs
(Compound 18)
PVA/PLGA-DEPLGA@AuNPs
(Compound 19)

Slope (A/sec)
1.0x10-2 ± 0.04
7.58x10-2 ± 0.003
4.73x10-2 ± 0.009

φsample
0.0371
0.2795
0.1743
N/A

QY%
3.71% ± 6.8x10-4
27.95% ± 6.4x10-3
17.43% ± 1.7x10-3

3.72x10-2 ± 0.002

0.1372

13.72% ± 2.1x10-4

2.01x10-2 ± 0.002

0.1509

15.09% ± 2.5x10-3

Comparing the two different light sources in terms of ROS and Figure 19, the 300 nm
emission light bulbs showed improved ROS generation from the even distribution and little
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error between the different replicates. Having a wider range of emission allowed for a higher
ROS generation as it was not a small window that the particles had to absorb at.

D. Conclusions
The main goal of this project was to synthesize and characterize the molecule listed in Figure 5
and determine the quantum yield of ROS when exposed to UV light. Based on the NMR spectra
for the listed polymers and ligands, the ligands were successfully synthesized and did not
degrade over time (lack of discoloration and physical properties over time and follow up
characterization). While attempts at reducing the dithiolane bond in the LA-EG end group were
not successful, following attempts to use biphasic ligand exchange method was successful. Not
only did the AuNPs that underwent ligand exchange disperse readily in chloroform (something
Cit@AuNPs does not do), but they also maintained stability in solution over a period of a couple
days (remained the same vibrant pink to purple color and no visible aggregates). The success is
also backed up by the spectral data provided – widening and shifting of peaks in 1D proton
NMR, the long range (NOE) interaction between the tail of the polymer and the AuNPs surface
in the 2D NMR, and the increase in size in DLS.
The co-precipitation of compounds 14, and 15 were successful in encompassing several
particles of gold as shown by STEM, the increase in size based in DLS, as well as the visible color
change in the solution – going from vibrant pink to clear and colorless – but still showing a
plasmon resonance at around 520 nm. This shows that there are gold particles within the
solution but at a low concentration. However, it was still enough to generate ROS and over a
prolonged period.
This project succeeded in synthesizing and characterizing PLGA-capped gold
nanoparticles and developed the method for generating ROS and calculating quantum yield of
those particles.

E. Future Work
The main future of this work would be to use an X-ray source to excite the gold nanoparticles
and not simply a UV light as UV is harmful to humans and can cause lasting damage if exposed
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for too long. This is one of the short-term future goals of the project and beyond that, there are
many other long-term goals that could be considered.
While this work shows that the functionalized gold nanoparticles show increased ROS
generation, there are still other aspects that can be optimized to increase the efficacy of the
particles. The future work of this project can include being more selective of the molecular
weight of the polymer. The main MW that this project aimed for was around 2000 MW which
was achieved, but studies could be done to see the impacts of a higher or lower MW on the
ROS generation and what the optimal length of the polymer chain should be. On a related topic,
the ratio of DL-lactide and glycolide could be explored to determine whether this causes any
noticeable impact on the efficacy of the AuNPs to generate ROS.
The method of nanoprecipitation could also be optimized by using different molecular
weight PVA. The biggest hypothesis to test would be determining the effects of higher versus
lower molecular weight. Would a lower molecular weight PVA allow for a more uniform shell
around the polymer, or would a different water soluble and bio-compatible polymer be more
ideal? These are experiments that would allow for a higher optimization as the un-precipitated
AuNPs show promise with ROS generation.
Another deciding factor on the optimization of the procedure would be to test the
different conditions of the Cit@AuNPs (i.e. crude vs. washed) and their impact on the success of
the ligand exchange.
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Appendix
Appendix A. Sample preparation and parameters
Characterization Technique
Parameters
Gas Permeation
Run against poly(styrene) standards [1300; 4000; 17,500;
Chromatography
65,000; 150,000 MW] in THF
Ionizing agent: silver trifluoroacetate in THF; Matrix: trans-2Matrix Assisted Laser
[3-(4-tert-butylphenyl)-2-methyl-2Desorption Ionization
propenylidene]malononitrile (DCTB) in THF at 20 mg/mL;
sample dissolved in THF at 1 mg/mL
Standard 8 mm NMR tubes: ~15 mg of sample dissolved in
0.67 mL of CDCl3
Nuclear Magnetic Resonance
Low Concentration 3 mm NMR tubes: 2 mg of sample in ~0.3
mL of CDCl3; 64 scans, 5 second relaxation time
Two samples prepared in 3 mm NMR tubes
2D Nuclear Magnetic
1) Compound 9: ~5 mg dissolved in 0.3 mL of CDCl3
Resonance
2) Compound 14: ~2mg dissolved in 0.3 mL of CDCl3
~15 mg of sample placed on platinum pan; Ramp to 100 °C at
Thermogravimetric Analysis
20°C/min; Isotherm at 100 °C for 30 min; Ramp to 900 °C at
10 °C/min
Lacey carbon formvar grids used for sample preparation;
Scanning Transmission Electron
diameter sizing based on 100 replicates unless otherwise
Microscopy
stated
~2.5mL of sample placed in glass cuvette; based on 70
Dynamic Light Scattering
replicates
UV-Vis Spectrophotometry for
~2 mL of sample placed in four-sided quartz cuvette with 1
ROS studies
drop of DPBF (1.39x10-4 M)
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Appendix B. Spectral data of D,L-lactide and glycolide monomers.

NMR Tabulation
D,L-Lactide: 1H NMR (500 MHz, CDCl3) δ 5.12 – 4.99 (m, 2H), 1.66 (d, J = 6.7 Hz, 6H).
Glycolide: 1H NMR (500 MHz, CDCl3) δ 4.95 (s, 4H)
IR Data:
D,L-Lactide: 3005.7 (sp2 –CH), 2925.9 (sharp sp3 –CH), 1751.3 (sharp C=O), 1250.3 (sharp C-O)
Glycolide: 2974.23 (weak sharp sp3 –CH), 1735.6 (broader sharp C=O), 1289.68 (broader sharp
C-O)
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Appendix C. Spectral data comparing Compound 6 to Compound 8.

NMR Tabulation:
Compound 6: 1H NMR (500 MHz, CDCl3) δ 3.62 – 3.53 (m, 2H), 3.23 – 3.07 (m, 4H), 2.51 – 2.42
(m, 1H), 2.38 (t, J = 7.4 Hz, 4H), 1.96 – 1.86 (m, 2H), 1.70 (s, 0H), 1.50 (s, 0H).
Compound 8: 1H NMR (500 MHz, CDCl3) δ 4.25 – 4.19 (m, 4H), 3.87 – 3.80 (m, 3H), 3.62 – 3.53 (m, 2H),
3.23 – 3.07 (m, 4H), 2.51 – 2.42 (m, 1H), 2.38 (t, J = 7.5 Hz, 5H), 1.96 – 1.85 (m, 4H), 1.68 (s, 0H).

IR Data:
Compound 6: 2928.4 (sharp sp3 –CH and broad carboxylic acid –OH), 1686.2 (sharp C=O)
Compound 8: 3427.9 (broad -OH), 2927.5 (sharp, sp3 -CH), 2857.1 ( sharp, sp3 -CH), 1730.8 (
sharp, C=O)
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Appendix D. NMR spectra comparing LA-EG with ring opening by Bu3P and NaBH4.
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Appendix E. MALDI data of Compound 9.

Table EI. Practiced conditions for the three major populations in the sample.

*Residual value = the value left over based on the MW after using set conditions (i.e. what’s left
of the molecular weight after subtracting the necessary end groups that isn’t accounted for).
+Predicted conditions = programed end groups and cations that could be impacting the
molecular weight (e.g. 250.07 g/mol is the molecular weight of the dithiolane end group)
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Appendix F. UV-Vis of MB control with linearized plot.
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